Coherus Oncology Jefferies Global Healthcare Conference
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Good morning. I'm Denny Lanfear, CEO of Coherus Oncology. It's my pleasure today to talk to you about our clinical programs, as well as LOQTORZI, our commercial asset. I want to first thank the organizers for inviting us to the conference this year and apprise you of our FLS and our forward-looking statements. Today, first of all, I'll talk a little bit about the corporate strategy and a summary of that. I'll spend the majority of my time, my remarks, with respect to tagmokitug, which is our T regulatory cell depleter and our recently completed clinical program of six different indications, which is very exciting, and our selection of esophageal cancer going forward. Then I'll talk a little bit about casdozokitug, which is our first-line HCC study for us. The investment thesis for the company is threefold.
First of all, a best-in-disease IO pipeline with tagmokitug across both first-line and second-line esophageal cancer, and both etiologies, both squamous and adeno. As I'll talk a little bit in a moment, this is some 400,000-500,000 patients globally and represents a substantial unmet medical need for patients. We have, I think, really just extraordinarily good clinical results that we have seen. LOQTORZI is our foundation PD1. It's approved and commercialized in nasopharyngeal cancer. I'll talk to you a little bit about that and how we're moving the market forward there, both in 2026 and 2027. Recently, we have right-sized the organization, having completed so many clinical trials, completed transition services agreements to support the divestiture of our biosimilar business, and then a few other things having to do with bringing our production of LOQTORZI into the U.S.
We're able to right-size our organization, reducing our headcount from about 140 to about 100 folks, reducing our quarterly burn $6 million-$7 million, and very importantly, reducing the hurdle rate where we need to do sales to reach our core cash burn down to about $25 million-$30 million from $30 million-$35 million per quarter. This is our pipeline. As you can see here in the middle with the tagmokitug in purple, there's a number of studies. I'll talk to you about this just in a little moment, but I think that we had a very comprehensive set of studies going across various indications. We still have one very interesting study, which you see here at the bottom, and that is in conjunction with our good friends at J&J for pasritamig, which is a T-cell engager. This is in prostate. I don't have any slides on pasritamig for you today.
We're starting that study. I think we're going to inject the first patient either this week or next week. What's very interesting about this is T-cell engagers require T-cells to engage with in the tumor microenvironment. If you successfully deplete the T regulatory cells, we have demonstrated remodeling of the tumor microenvironment and the ability for it to be infiltrated by fresh T-cells. We have selected esophageal cancer for follow-on development. I would just, regarding the first point here about we believe we have the right drug with the right target and focused on the right indication. Others have had a problem with T regulatory cell depletion. There's been deficits with pharmacology. This is actually a very difficult target. It's a GPCR receptor, I'll remind you.
That means there's a very small amount of real estate protruding from the surface of the receptor. Therefore, it's very difficult to get a highly selective antibody to address that. We feel we have a best-in-class antibody, which has shown very good safety, high selectivity, and I'll show you that safety data subsequently in the studies that we have done. I'll also show you, of course, our results in both first-line and second-line esophageal, which handily exceed standard of care. Then I'll talk a little bit further about the market size and how, really, this integrates well with our plans for global partnering this asset. One of the key issues that's very convenient for us as we look forward is the very high incidence of esophageal cancer, for example, in Asia. This, we feel, will allow us to find strong partners to help us.
As I indicated a moment ago, we conducted a strategic prioritization after completing all of these studies and right-sized our organization. This was facilitated by, of course, reducing the number of studies from seven, very much focused really on esophageal. Secondarily, though, it allowed us to focus the company and all the folks that were there really on just what we really need to do to get that done. As I said, we'd right-sized it down from about 142 to about 100 FTEs, really without impairing our functionality at all as we have really focused. I would just say since we've evolved out of the biosimilar business, we have continually refined the company and reduced the size of it. Lastly, one of the things we'll do is focus on getting to core burn break-even, and I talked about this just a second ago.
The hurdle right now here is down to $25 million-$30 million, which we feel we can handily get to next year. I just want to remind you of the action of when you overcome immune resistance and its benefit to patients. What you see here is the Kaplan-Meier curve actually for nasopharyngeal cancer for LOQTORZI. 64.8 months in combination with chemotherapy versus 33.7 months on chemo alone. Really a significant benefit. This shows you that the benefit to patients accrues at the far end of the curve. Early on in the first three, six, nine months where you see the initial scans and you see the initial ORR, you really don't see a breakout difference between immunotherapy and, for example, chemotherapy. But this really is what's important to patients. Survival is the approval endpoint in the United States, as you know.
Toripalimab is really an extraordinary molecule that's shown strong activity across indications, but particularly in esophageal cancer. I direct you to the left side of this, where you see two histograms demonstrating that it is equipotent with low PD-L1 and high PD-L1 in esophageal cancer on a background of chemotherapy, versus you see here's KEYTRUDA, KEYNOTE-590, where it is not. As a matter of fact, KEYTRUDA, OPDIVO, and TECENTRIQ all had their labels removed in the United States for low PD-L1 patients. Further to the point, this is approved in Europe with both low and high PD-L1 and doing very well. This is a very clinical meaningful difference, of course, as I just outlined, the six-year survival, and we've been able to translate that to the NCCN guidelines, where we are the only product that is in first position.
With respect to our commercial strategy then, we are growing the revenues steadily. We guided earlier this year to achieving $15 million per quarter. We feel quite confident we will do that next quarter. This quarter, we did about $14 million. We will hit somewhere around $30 million per quarter in one of the quarters in 2027, and that should get us to core burn break-even with the company. Then, ultimately, we see this market, which is about a $250 million overall market, that we should be able to do about $40 million plus per quarter there. The drivers on that, first of all, are the survival data. Secondarily, the investments we made in getting the claims data, so we can go to the physicians and the institutions where the patients are.
Lastly, we also made some other investments in our field footprint of adding additional territories so we could actually go into our alert system and have faster follow-up on those patients. Let me talk a little bit now about the very exciting clinical results, tagmokitug. Let me first take a step back and remind you about Tregs. They have a fundamental role in mediating immune homeostasis. This is particularly of interest in the mucosal system, right? Everything from the mouth, the esophagus, gastric, all the way down to CRC. What this does then is that as it is invaded by pathogens and food and all these things, the T regulatory system really moderates on a very dynamic basis the immune response. What this means, though, is this is the way cancer basically hijacks this response, creates immune resistance, and then grows.
Therefore, we thought that this was the ideal place to pursue an evaluation, and we went after each of these cancers, head and neck with squamous, and then esophageal carcinoma, upper GI, and then all the way to CRC. Significantly here, we pursued esophageal both in the context of squamous and adeno etiologies. You see that here. This is some of our results. I will dive into this and show you the actual data in just a moment. But here is the first-line esophageal data that you see. What is really remarkable about this, in the PD-L1 high patients, we saw a 100% response rate. 100% response rate, which compares to about a 50% response rate of standard of care, which is basically a PD-1 and chemotherapy. With esophageal, we saw a 33% response rate confirmed and a 44% response rate unconfirmed.
This is really remarkable insofar as the standard of care for second-line esophageal for both etiologies is chemotherapy, 10% response rate. This is really strong data and puts us in a position really where we can focus on esophageal both first and second line with the FDA going forward, and I will tell you about how we are going to do that in just a moment. Here is the setup for our studies. The first-line study was 12 patients. Second study was 20 patients split between high and low dose, and I will show you the dose response data, which is also very, very clean in just a moment. Then lastly, gastric, 40 patients across gastric, the esophageal, and so forth, primarily adenocarcinoma patients. This is the waterfall for the first-line esophageal. Very, very compelling, as you can see. 75% confirmed overall response rate, 100% ORR.
This really, 100% of the patients here showed tumor shrinkage. Remarkably, there was also activity in PD-L1 low and also very, very strong activity. The enrollment's ongoing. I think we got 11 patients in so far. We have one more to go here. This is really very, very encouraging. What I really like about this is it really is highly consistent with what toripalimab has shown in the past with respect to its activity in esophageal, only far better. This is our complete response patient, 88% reduction in the target lesions at time of the response. This is a PD-L1 positive patient. In this patient, really, you can see the mass and the diminution of the mass at the follow-ups. Here, for example, you can see the duration, and this is really, really important. You see the patients going out.
Here's our complete response patient, and you can see the duration. I started the presentation by showing you the responses with toripalimab on a background of chemotherapy in nasopharyngeal cancer and that very long duration benefit to patients. You see the very same thing here. This is really indicative of what you want to get when you overcome immune resistance for the patients, right? You don't get this huge ORR usually right in the front, but you get this very nice duration, which has significant benefit. Let me switch gears now and talk about esophageal, and there's two etiologies here, squamous and adeno. We looked at each of them at two different doses here. You can see the upper in the green, we have the low dose, which is the 300 mgs. Down below in purple, you see the high dose, which is 700 mgs.
What's really striking about this is really the stellar dose response that you see with these patients. The other thing that happened here, of course, was again, the duration, 5.5 months with respect to the progression-free survival. That compares handily with the standard of care at chemo, which is 2.5-3.5 months. This really sets us up really nice for conversations with the FDA, and I'll talk to you in just a second about our plans to go forward with that. Here's the waterfall chart for these patients, and you can see, the thing that I would point out here also is we also did circulating tumor ctDNA levels, which tracked along very, very nicely with the overall waterfall and the overall response. With respect to that, you see here we have a 55.6% clinical benefit rate, which is really outstanding.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
2 people spoke on this call — only 1 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
